APM
KNSA icon

Avidity Partners Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Avidity Partners Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,330,700
Closed -$24.6M – 133
2021
Q1 		$24.6M Buy
1,330,700
+365,400
+38% +$7.47M 0.68% 50
2020
Q4 		$17.1M Buy
+965,300
New +$17M 0.55% 53

Other funds holding KNSA

PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Avidity Partners Management's KNSA Position: Q2 2021 in Review

Avidity Partners Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2021, closing a stake of 1,330,700 shares — an estimated $24.6M sold.

Avidity Partners Management first reported a position in KNSA in Q4 2020 and held it in 2 quarters. The position peaked at $24.6M in Q1 2021. 102 funds tracked by Wall St. Rank hold KNSA as of Q2 2021.

  • Avidity Partners Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • Avidity Partners Management sold 1,330,700 Kiniksa Pharmaceuticals shares in Q2 2021, an estimated $24.6M.
  • Avidity Partners Management first reported a position in Kiniksa Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • Avidity Partners Management's Kiniksa Pharmaceuticals position peaked at $24.6M in Q1 2021.
  • 102 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2021.

Based on Avidity Partners Management's 13F filing for Q2 2021, filed 16 Aug 2021.